Bernard Doger

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Tumor-type specific methylation patterns of MTAP in human samples and cell lines.

Tumor-type specific methylation patterns of MTAP in human samples and cell lines.

Journal: Clinical epigenetics
Published: January 17, 2026

Landscape of T-cell engagers in solid tumors.

Landscape of T-cell engagers in solid tumors.

Journal: The oncologist
Published: October 01, 2025

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2025

Evolution of bispecific and multispecific antibodies in cancer therapy.

Evolution of bispecific and multispecific antibodies in cancer therapy.

Journal: The Lancet regional health. Europe
Published: May 26, 2025

BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.

BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.

Journal: ESMO open
Published: April 25, 2025

Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study.

Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study.

Journal: JTO clinical and research reports
Published: May 13, 2024

A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer.

A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer.

Journal: The oncologist
Published: May 13, 2024

Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut.

Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut.

Journal: Cancers
Published: May 05, 2024

In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations.

In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations.

Journal: Scientific reports
Published: April 24, 2024

Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors.

Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors.

Journal: Cancer immunology, immunotherapy : CII
Published: March 22, 2024

Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives.

Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives.

Journal: Cancer treatment reviews
Published: March 13, 2024

Prolonged survival in a patient with pbrm1 mutated metastatic cholangiocarcinoma receiving tazemetostat.

Prolonged survival in a patient with pbrm1 mutated metastatic cholangiocarcinoma receiving tazemetostat.

Journal: NPJ precision oncology
Published: March 12, 2024
Showing 1-12 of 34

Last Updated: 09/26/2026